Innate Pharma S.A. (IPHA) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Molecular Partners (MOLN) has outperformed Innate Pharma S.A. (IPHA) over the past year, gaining 2.7% versus a loss of 22.1%. Over five years, IPHA leads with a -74.1% price change compared with -80.8% for MOLN. Innate Pharma S.A. is the larger company by market cap ($168.7 million vs $145.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPHA | MOLN |
|---|---|---|
| Share price | $1.51 | $3.81 |
| Market cap | $168.67M | $145.94M |
| 1-day change | -0.67% | 0.00% |
| YTD return | -13.14% | -12.59% |
| 1-year return | -22.05% | +2.70% |
| 5-year return | -74.11% | -80.76% |
| EPS (TTM) | $-0.59 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.71 | $5.36 |
| 52-week low | $1.17 | $3.53 |
| Distance from 52-week high | -44.28% | -28.92% |
| Analyst consensus | none | none |
| Avg. price target upside | +341.72% | +172.18% |
| Average volume | 156.71K | 1.18K |
| Shares outstanding | 111.70M | 38.31M |
| Employees | 120 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed IPHA by 24.7 percentage points over the past year.
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
IPHA vs MOLN FAQ
Which is bigger, Innate Pharma S.A. or Molecular Partners?
Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $168.67M compared with $145.94M for Molecular Partners (MOLN).
Which stock has performed better over the past year, IPHA or MOLN?
MOLN returned +2.70% over the past 12 months, compared with -22.05% for IPHA (price return, excluding dividends). Past performance does not predict future results.
Are Innate Pharma S.A. and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.